The efficacy and safety of bamlanivimab

treatment against COVID-19: A

meta-analysis

- 4 Huai-rong Xiang ^a, Bei He ^a, Yun Li ^a, Xuan Cheng ^a, Qi-zhi Zhang ^a,
- 5 Wen-xing Peng a, b *

1

2

3

10

- ^a Department of Pharmacy, the Second Xiangya Hospital, Central South
- 7 University, Changsha, Hunan 410011, China
- 8 b Institute of Clinical Pharmacy, Central South University, Changsha, Hunan
- 9 410011, China
- 11 *Corresponding author:
- 12 Phone: 0086-0731-88836044; Fax: 0086-0731-88836044
- Email address: pwx.csu@csu.edu.cn
- 14 Full postal address: Department of Pharmacy, the Second Xiangya Hospital,
- 15 Central South University, #139, Middle Renmin Road, Changsha, Hunan 410011,
- 16 P.R. China

17

18 The full text words: 4378

Key points

19

29

20 **Question:** Can bamlanivimab treat COVID-19 patients? What are the factors 21 that have great impact on the treatment outcome? 22 **Findings:** In this meta-analysis that retrieved 3 RCTs and 7 cohort studies and 23 included 14461 adults, Bmlanivimab may help outpatients to prevent hospitalization 24 or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission 25 (RR 0.47 95% CI 0.23 to 0.92) and mortality (RR 0.32 95% CI 0.13 to 0.77) from the 26 disease. 27 **Meaning:** In COVID-19 pandemic, the use of bamlanivimab may be warranted. 28 Combinations of two or more monoclonal antibody increase the effect.

ABSTRACT

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Background: Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19. Methods: We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19. Results: Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome. Conclusion: Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab are warranted in the future.

Key words: bamlanivimab; COVID-19; Immunotherapy

INTRODUCTION

54

55

56 The Coronavirus disease 2019 (COVID-19) has become a major public hazard 57 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By 58 August 2021, more than 203 million people have been reported to be infected with 59 COVID-19, and 4 million people have died of it. Although the advent of vaccines 60 has played a great role in epidemic prevention and control. In developing countries, the availability of vaccines has been slow^[1]. Several of these COVID-19 therapeutic 61 62 candidates are currently being studied in preclinical and clinical research stages 63 around the world. Antibody based on viral spike protein (S protein) appears to be the main target of antibody development candidates^[2]. 64 65 Bamlanivimab, also known as LY-CoV555, is a lgG monoclonal antibody 66 which mediate its effects by means of binding with the receptor-binding domain of 67 SARS-CoV-2 to viral neutralization, complement activation and antibody-dependent cellular cytotoxicity^[3, 4]. In November 2020, the Food and Drug Administration 68 69 (FDA) authorized an emergency use authorization (EUA) for bamlanivimab, for 70 treatment of mild to moderate COVID-19 in non-admitted patients at high risk for severe disease^[5]. The benefits or harms of such monoclonal antibodies is limited. 71 72 Thus, this meta-analysis, aims to summaries efficacy of bamlanivimab use in 73 COVID-19 based on available evidence and find out the potential association 74 between treatment with bamlanivimab and outcomes of COVID-19.

METHOD

75

76

77

78

This meta-analysis was described by the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P) statement^[6]. and the guidelines of the Meta-analysis of Observational Studies in Epidemiology^[7]. The protocol for

79 this study has been registered in the International Prospective Register of Systematic

Reviews (PROSPERO, CRD42021272789).

80

81

82

83

84

85

86

87

89

91

92

93

94

95

96

97

98

99

100

101

Search strategy and study selection

Two experience researchers (Bei He and Xuan Cheng) based on The Peer Review of Electronic Search Strategies checklist^[8] searched Web of Science, PubMed, Embase, the Cochrane Library, MedRxiv for clinical trials and observational studies. A combination of search terminologies ("Coronavirus Disease 2019" OR "COVID-19" OR "SARS-Cov-2" OR "2019-nCoV Diseases" OR "COVID 19 Virus Infection") AND ("LY-CoV555" OR "bamlanivimab"). Search 88 was down on August 5, 2021 which was imposed restriction on the date between 1.1 2020 to 8.5 2021. No restriction on the geographical location or language of the 90 studies. To be eligible for inclusion, studies must divide patients into treatment group using bamlanivimab and control group with no bamlanivimab. We also required that the studies reported data on any of the pre-determined outcomes. The studies aimed at preventing the occurrence of COVID-19 were excluded.

Data extraction

Two reviewers (Huai-rong Xiang, Yun Li) independently screened the titles and abstracts of the studies to retrieve articles and extracted data based on the inclusion and exclusion criteria. Any discrepancies will be resolved through discussion (with a third author, if necessary).

Each included article was thoroughly reviewed, the following data and information were extracted:

- (1) The first author's name, publication date, country and study type.
- 102 (2) Patients' information
- 103 (2) Treatment plan (including dosage, timing of using bamlanivimab).

(3) Outcome indicators.

Data was extracted and entered to a pre-defined and piloted Microsoft excel

database.

Quality assessment

Two reviewers (Qi-zhi Zhang and Huai-rong Xiang) independently evaluated the quality of these literature. In case of any disagreement, the third reviewer (Yun Li) consulted for reconciling any difference of opinion. The version 2 Cochrane Risk of bias Assessment tool^[9] was used to evaluate the methodological quality of the RCTs over five domains of selection, performance, blinding, completeness, and reporting. For each domain, risk of bias judgements is 'high', 'unclear' or 'low'. The Newcastle-Ottawa Scale (NOS)^[10] was to evaluate the quality of the cohort studies which comprises three parts of patient selection, comparability, and research results. The total score is 9 which was divided into three categories: (a) high risk (1-3); (b) some concerns (4-6); (c) low risk (7-9).

Outcomes and subgroup analyses

Primary outcomes were subsequent hospitalization or emergency department (ED) visit, all-cause mortality. Secondary outcomes were admission to intensive care unit admissions. We conducted a priori determined subgroup analyses to explore the source of heterogeneity among observational studies. We performed stratified analyses by (1) the dose of bamlanivimab (700mg, 2800mg, 7000mg and combination) (2) 14 days or 28 days outcomes.

Statistical Analysis

All statistical analysis was conducted by Stata 16 (StataCorp, College Station, SE) software. Statistical heterogeneity was evaluated by the I-squared (I²) test. A

fixed-effect model was selected if $I^2 < 40\%$. When I^2 value > 40%, heterogeneity was considered significant, and the random-effect model was applied. We used relative risk (RR) for dichotomous data with 95% confidence interval (CI). Publication bias was detected using Egger's test.

Certainty of evidence

- The certainty of evidence was rated using the Grading of Recommendations,
- 134 Assessment, Development and Evaluations (GRADE) approach.

RESULTS

Search results and study characteristics

As shown in Figure. 1, the total search process yielded 460 records. Following removing duplicates publications 243 studies were remained. After screening of titles and abstracts we excluded 156 studies as these include reviews, commentaries, mechanism researches, and irrelevant to COVID-19. After comprehensively screening 77 full texts and assessment of risk of bias, only 10 eligible studies were included, 3 RCTs^[11-13] and 7 observational studies^[14-20]. We considered observational studies with an NOS score ≥6 with high quality. (Figure 1) All studies included were conducted in America. Assessment of bias for the 9 observational studies revealed a moderate risk of bias as assessed against various quality parameters. (Supplementary table 1). 3 RCTs were classified as low risk because they have been clinically registered in USA National Institutes of Health Register (ClinicalTrials.gov) and had registration numbers. (Supplementary table 2). Two RCTs^[11, 12] shared one registration numbers (NCT04427501), but the patients were enrolled at totally different time. One RCT^[11] has four bamlanivimab arm for the

dose. Owing to the different dosage and limited studies, we conducted a subgroup analysis based on the infusion time at 700 mg bamlanivimab.

Outcome of bamlanivimab for COVID-19

Hospitalization or ED visit

Eleven trials (n = 14152 participants) reported on hospitalization or emergency department visit. The use of bamlanivimab compared to placebo could reduce the risk of hospitalizations or emergency department visit (RR 0.41, 95% CI 0.29 to 0.58; I^2 = 77.3%, P = 0.000) with low certainty of evidence. (Figure 2) Sensitivity analysis after deleting the study successively revealed the same high heterogeneity.

Mortality

Nine trials (n = 13298 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of mortality (RR 0.32, 95% CI 0.13 to 0.77; I^2 = 47.5%, P = 0.064 low certain of evidence). (Figure 3) We conducted a sensitivity analysis to investigate the source of the heterogeneity. The study conducted by Lundgren et al. included hospitalized patients and the heterogeneity may be caused by different degrees of severity of the disease in the participant. After excluding that study, the heterogeneity decreased significantly (I^2 = 9.4%), and the results showed that the bamlanivimab could significantly decrease the rate of mortality. (RR 0.2 95%CI 0.10 to 0.40)

ICU admission

Only two trials (n = 5073 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of ICU admission (RR 0.47, 95% CI 0.23 to 0.92; I^2 = 0.0%, P = 0.672 low certainty of evidence). (Figure 4) We did not perform sensitivity analysis.

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Safety In this meta-analysis, 3 RCTs^[11-13] reported adverse effects. The pooled result from three trials (n = 1873 participants) found bamlanivimab increased the risk of serious adverse events but no statistic difference. (RR 1.33 95% CI 0.84 to 2.10; $I^2 =$ 0%, P = 0.783 high certainty of evidence) (Figure 5) We did not perform sensitivity analysis about this result. **Subgroup Analysis** Subgroup analysis based on dose Subgroup analysis showed that the 700mg single bamlanivimab and 2800mg bamlanivimab plus 2800mg etesevimab could reduce the risk of hospitalizations or ED visit compared with the control group. And the combination of two antibodies could reduce more risk than 700mg single antibody (RR:0.29 VS 0.59). Due to only one study in the 2800mg single dose and 7000mg dose, there are no statistic difference between treatment and control group. (Figure 6) In the part of mortality, there was no significant difference among 7000mg treatment group and control group. Both 700mg and 2800mg bamlanivimab plus 2800mg etesevimab could decrease the mortality (700mg: RR 0.33 95%CI 0.18 to 0.58; $I^2 = 0\%$, P=0.799. 2800mg bamlanivimab plus 2800mg etesevimab: RR 0.05 95%CI 0.00 to 0.81) (Figure 7) Risk of publication bias Assessment of publication bias using Egger's test showed that there was significant potential publication bias among the included trials hospitalization or ED visit (p=0.001) and mortality (p=0.006). (Supplementary Figure 1)

DISCUSSION

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

This is the first meta-analysis included 3 RCTs and 9 observational studies investigating the effect of bamlanivimab with or without etesevimab on clinical outcomes. Despite our inclusion criteria that did not specify the severity of the disease, all the studies were conducted with non-hospitalized patients except the RCT by Lundgren 2020 et al^[13]. This study provided better evidence for COVID-19 treatment decisions through systematically reviewed, summarized evidence. And our meta-analyses suggested that bamlanivimab may help outpatients to prevent hospitalization, reduce severity and mortality from the disease. What's more, the combination of bamlanivimab and etesevimab could play a bigger role in the outcomes. Last but also important, early treatment is more effective. There is slightly trend on increasing serious adverse events. The certainty of the evidence of the all-cause hospitalization or ED visit and mortality was low. All observational studies adjust the age confounders, but patients in exposed group had higher risk factor for severe COVID-19 than nonexposed group. And there still was a trend toward a lower risk of hospitalization in bamlanivimab treated patients. Most studies' patients we included were at mild or moderate severity COVID-19. Only one RCT^[13], included hospitalized patients whose infusion time was within 12 days of symptom onset, which announced that no clinical benefit of bamlanivimab administration in patients with already present symptoms of COVID-19. Another study^[21] showed the contrary results which only treated to hospitalization. But early intervention of this study is rather comparable to the recently outpatient studies. It has been proposed that bamlanivimab has ability to neutralize the spike protein of SARS-CoV-2 and consequently block attachment to the human angiotensin-converting enzyme 2 (ACE-2) receptor and deny host cell entry. The FDA announced that bamlanvimab has a definite therapeutic effect on COVID-19. However, Lilly, the company that makes bamlanivimab suggested that it would be

unlikely to help patients who admitted to hospital with COVID-19. What's more, potential drawbacks of monoclonal antibodies have also become clear, such as immune escape by selection of viral mutations^[22]. For instance, E484K-carrying SARS-CoV-2 variants could resistant to bamlanivimab which emergence and expansion of had been at least partially underestimated^[23] And bamlanivimab lost its ability to bind to the spike protein and no longer neutralized the Delta variant [24, 25]. Combinations of two or more monoclonal antibodies or polyclonal antisera may therefore increase the barrier sufficiently to prevent escape of the immune system as known from other viral infections^[26]. There are some limitations on our meta-analysis. First, groups in some studies were unlikely considered to be comparable on each variable used in the adjustment such as immunosuppression and comorbidity. Second, the small number of participants in some RCTs may increase the likelihood of type II statistical error. Larger scale RCTs are required to confirm the findings. Third, the primary focus of this meta-analyses was cohort studies. Theoretically, observational studies would overestimate the treatment effect of the interventions [27]. Fourth, the data were too limited to perform more meaningful outcome or subgroup analyses. Fifth, the results of egger's test mean there were high risk of selective reporting or of publication bias.

Conclusion

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

Our study showed that bamlanivimab has might be beneficial for mild or moderate ill patients with COVID-19. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab are warranted in the future.

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

Authors' Contributions Wen-xing Peng, and Huai-rong Xiang designed this study; Xuan Cheng and Bei He ran the searched strategy; Huai-rong Xiang and Yun Li selected articles and extracted data; Qi-zhi Zhang and Yun Li evaluate the quality of the literature. Huai-rong Xiang wrote the manuscript, Xuan Cheng, Yun Li, Bei He and Qi-zhi Zhang edited. All listed authors reviewed and approved the final manuscript. **Competing interests** The authors declared there are no competing interests. Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. The data are available by accessing the published studies listed in table 1. Acknowledgments None Reference [1] Tyagi K, A Ghosh, D Nair, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15(3):1007-1008. [2] Baral PK, J Yin, MNG James. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol. 2021;186:490-500.

271 [3] Casadevall A, E Dadachova, LA Pirofski. Passive antibody therapy for 272 infectious diseases. #N/A. 2004;2(9):695-703. 273 [4] Dale AP, MJ Hudson, T Cullen, et al. Administration of Bamlanivimab to 274 Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 275 2021, Arizona. J Am Med Dir Assoc. 2021;22(7):1357-1358. 276 [5] COVID-19 news release: FDA authorizes monoclonal antibody for 277 treatment of COVID-19. US Food and Drug Administration website. . Available 278 from: 279 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-updat 280 e-fda-authorizes-monoclonal-antibody-treatment-covid-19. 281 [6] Moher D, A Liberati, J Tetzlaff, et al. Preferred Reporting Items for 282 Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 283 2009;6(7):e1000097. 284 [7] Stroup DF, JA Berlin, SC Morton, et al. Meta-analysis of observational 285 studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational 286 Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. 287 [8] McGowan J, M Sampson, DM Salzwedel, et al. PRESS Peer Review of 288 Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 289 2016;75:40-46. 290 [9] Higgins JP, DG Altman, PC Gotzsche, et al. The Cochrane Collaboration's 291 tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 292 [10] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the 293 assessment of the quality of nonrandomized studies in meta-analyses. Eur J 294 Epidemiol. 2010;25(9):603-605. 295 [11]Gottlieb RL, A Nirula, P Chen, et al. Effect of Bamlanivimab as 296 Monotherapy or in Combination With Etesevimab on Viral Load in Patients With 297 Mild to Moderate COVID-19: a Randomized Clinical Trial. JAMA. 298 2021;325(7):632-644.

299 [12] Dougan M, A Nirula, M Azizad, et al. Bamlanivimab plus Etesevimab 300 in Mild or Moderate Covid-19. New Engl J Med. 2021. 301 Lundgren JD, B Grund, CE Barkauskas, et al. A neutralizing [13] 302 monoclonal antibody for hospitalized patients with Covid-19. New Engl J Med. 303 2021;384(10):905-914. 304 [14] Rainwater-Lovett K, JT Redd, MA Stewart, et al. Real-world Effect of 305 Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in 306 the United States. Open Forum Infect Dis. 2021;8(8):ofab398. 307 Ganesh R, CF Pawlowski, JC O'Horo, et al. Intravenous bamlanivimab [15] 308 use associates with reduced hospitalization in high-risk patients with mild to 309 moderate COVID-19. J Clin Invest. 2021. 310 [16] Kumar RN, EL Wu, V Stosor, et al. Real-World Experience of 311 Bamlanivimab for COVID-19: A Case-Control Study. Clinical infectious diseases: 312 an official publication of the Infectious Diseases Society of America. 2021. 313 Iqbal L, TJ Terlau, A Hernandez, et al. Efficacy of Bamlanivimab in [17] 314 Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural 315 Community. Cureus. 2021;13(7). 316 [18] Destache CJ, SJ Aurit, D Schmidt, et al. Bamlanivimab Use in 317 Mild-to-Moderate COVID-19 Disease: A Matched Cohort Design. Pharmacotherapy. 318 2021. 319 [19] Bariola JR, EK McCreary, RJ Wadas, et al. Impact of Bamlanivimab 320 Monoclonal Antibody Treatment on Hospitalization and Mortality among 321 Nonhospitalized Adults with Severe Acute Respiratory Syndrome Coronavirus 2 322 Infection. #N/A. 2021;8(7). 323 [20] Webb BJ, W Buckel, T Vento, et al. Real-world Effectiveness and 324 Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early

COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331.

326 [21] Koehler J, B Ritzer, S Weidlich, et al. Use of monoclonal antibody 327 therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe 328 COVID-19: experience from a tertiary-care hospital in Germany. Infection. 329 2021:1-6. 330 [22] Schoofs T, F Klein, M Braunschweig, et al. HIV-1 therapy with 331 monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. 332 Science. 2016;352(6288):997-1001. 333 [23] Tuccori M, I Convertino, S Ferraro, et al. An overview of the 334 preclinical discovery and development of bamlanivimab for the treatment of novel 335 coronavirus infection (COVID-19): reasons for limited clinical use and lessons for 336 the future. Expert Opin Drug Discov. 2021:1-12. 337 [24] Planas D, D Veyer, A Baidaliuk, et al. Reduced sensitivity of 338 SARS-CoV-2 variant Delta to antibody neutralization. Nature. 339 2021;596(7871):276-280. 340 [25] Connor BA, M Couto-Rodriguez, JE Barrows, et al. Monoclonal 341 Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta 342 (B.1.617.2) Variant Case. Int J Infect Dis. 2021. 343 [26] Margolis DM, RA Koup, G Ferrari. HIV antibodies for treatment of 344 HIV infection. Immunol Rev. 2017;275(1):313-323. 345 [27] Vandenbroucke JP. Why do the results of randomised and observational 346 studies differ? Bmj. 2011;343:d7020.




Figure 1: Preferred Reporting Items for Systematic Review and Meta- analysis (PRISMA) flow diagram for the systematic review and meta- analysis.




Figure 2: Forest plot of pooled hospitalization or ED visit rate across all included studies.

Weights are from random-effects analysis. Note: CI = Confidence Interval, ED = Emergency

Department




Figure 3: Forest plot of pooled mortality rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval.




Figure 4: Forest plot of pooled ICU admission rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval.




Figure 5: Forest plot of pooled serious adverse events rate across all included studies. Weights are from Fixed-effects analysis. Note: CI = Confidence Interval.




Figure 6: Forest plot for subgroup analysis of hospitalization or ED visit rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab




Figure 7: Forest plot for subgroup analysis of mortality rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab

Table 1 Characteristics of the studies included in the meta \square analysis

Frist author,	Type of	country	Mean age	Enrolled patients	Timing of using	Dose		Outcome
year	study		IQR or SD		bamlanivimab			
			(treatment					
			group)					
Dougan	RCT	USA	53.8±16.8	aged 12 years or older with mild or	Positive	a combination of	1.	the overall clinical status of the patients, defined as Covid-19–related hospitalization (acute care for ≥24 hours) or death from any cause by day
2021				moderate symptoms; with at least one	SARS-CoV-2 test ≤3	2800 mg of		as Covid-19–related hospitalization (acute care
				risk factor for severe Covid-19	SARS-COV-2 test \(\sigma\)	bamlanivimab and		ghts
					days before infusion	2800 mg of		for ≥ 24 hours) or death from any cause by day $\frac{\sigma}{2}$
						etesevimab or		29.
						placebo	2.	change from baseline to day 7 in the SARS-CoV-2
								viral load.
							3.	the time to sustained patient-reported resolution of
								symptoms.
Gottlieb	RCT	USA	44 (30-60)	aged 18 years or older, tested	Positive SARS-CoV-2	placebo,	1.	The change in log viral load from baseline to day &
2020				positive for SARS-CoV-2 infection,		700,2800 ,7000 mg		11. with
				had 1 or more mild to moderate	test ≤3 days before	of bamlanivimab,	2.	time to symptom improvement; time to symptom
				symptoms.	infusion	and a combination		resolution; and the proportion of patients showing
						treatment with 2800		
						mg of		symptom improvement or resolution at days 7, $11\frac{9}{5}$. 15, and 22)
						bamlanivimab and	3.	focused on clinical outcomes (the proportion of patients with a COVID-19–related hospitalization, emergency department visit, or death) at day 29
						2800 mg of		patients with a COVID-19-related hospitalization,
						etesevimab.		emergency department visit, or death) at day 29.
Lundgren	RCT	Denmar	63 (50–72)	adult hospitalized patients who	within 12 days of	7000mg of	1.	the time to a sustained recovery, which was defined as hospital discharge to home and
2020		k		had documented SARS-CoV-2	symptom onset	bamlanivimab		defined as hospital discharge to home and

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

				infection and a duration of symptoms attributable to Covid-19 of 12 days or			remaining at home for at least 14 days 2. death from any cause.
Bariola 2021	observational study	USA	67 .3 (13.0)	less. diagnosed mild to moderate COVID-19 (with a positive polymerase chain reaction or antigen test for SARS-CoV-2 virus); body mass at least 40 kg; age ≥65 years; or a medical condition conferring high risk of COVID-19 progression to severe disease and/or hospitalization	within 10 days of symptom onset	700mg of bamlanivimab	a composite of hospitalization or all-cause mortality during the follow-up windows. hospitalization or 28-day ED visit without hospitalization.
Destache 2021	Cohort	USA	72 (65-80)	one of the following risk factors: age greater or equal to 65 years, BMI greater than or equal to 35, chronic kidney disease, diabetes, immunosuppressive disease, immunosuppressive treatment, age greater than or equal to 55 years and cardiovascular disease, age greater than or equal to 55 years and hypertension, age greater than or equal to 55 years and chronic respiratory pulmonary disease or other chronic respiratory diseases, or	NA	NA	Subsequent hospitalization or an ED visit

				age less than 55 years with sickle cell				
				disease, congenital or acquired heart				
				disease, neurodevelopment disorders,				
				medical related technological device				
				dependence, asthma, or reactive				
				airway disease. Patients identified in				
				this report were then searched to				
				determine if they received BAM				
				treatment as part of their COVID-19				
				infection treatment.				
Ganesh	Cohort	USA	63 (52,72)	565	within 10 days of	700mg of	1.	All-cause hospitalization
2021	study			age ≥65 years, body mass index	symptom onset	bamlanivimab	2.	Intensive care unit admissions
							3.	Survival
				(BMI) ≥35, diabetes, chronic kidney			4.	Adverse Events
				disease, immunosuppressive				
				medication use, or an				
				immunocompromising condition.				
				Patients 55 years and older qualified				
				if they had hypertension,				
				cardiovascular disease, or chronic				
				lung disease. Mild or moderate				
Kumar	Case-contr	USA	66 (57–74)	Prescribing clinicians attested in the	<10 days from initial	single infusion of	1.	The primary outcome was hospitalization within
2021	ol study			bamlanivimab referral order that the	symptom onset, and	700 mg		30 days from initial positive SARS-CoV-2 PCR.
				patient (1) was not hospitalized at	<5 days from first			Demographics, comorbidities, and presentation
				time of order placement, (2) had no	positive SARS-CoV-2			characteristics were compared between cases ar
				acute need for oxygen therapy or, for	test.			controls.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

				those patients on oxygen at baseline, no increase in oxygen requirement, (3) was age 18 years or older, (4) had positive SARS-CoV-2 testing, (5) and whether the patient weighed ≥40 kg.			Secondary outcomes included: intensive care unit (ICU) admission, mechanical ventilation requirement, mortality, and duration of hospitalization within 30 days from first positive SARS-CoV-2 test. medical visit was defined as the first instance of
Rainwater 2021	Cohort study	USA	63.9 (15.9)	tested positive for SARS-CoV-2 via an antigen or polymerase chain reaction-based test. Patients with positive viral test results recorded in the electronic health record between July 1st and December 20th	with symptom onset within no more than 10 days.	NA	COVID-19-related E.D. visit or hospitalization after positive SARS-CoV-2 viral test result. 2. Adverse Events
Webb 2021	Cohort	USA	65 (13)	Patients were ineligible to receive MAb therapy for the following conditions: 1) hospitalized due to COVID-19, 2) new, COVID-related hypoxemia (defined as peripheral oxygen saturation <90% at rest or new supplemental oxygen requirement, or for those with chronic hypoxia, a new change in baseline saturation or oxygen demand, 3) pregnant, or 4) known hypersensitivity to other monoclonal drugs. Eligibility criteria for pediatric patients differed from adults and	with symptom onset within no more than 7 days.	700mg of bamlanivimab	The primary outcome was emergency department visit or hospitalization within 14 days of positive test.

\mathbf{a}	_
/	7


		patients <18 years of age are not	
		included in this study.	

Table 2. Outcome summary

Outcome	Study(n)	RR	95% CI
Hospitalization	9	0.41	(0.29, 0.58)
or ED visit			
Mortality	8	0.32	(0.13, 0.77)
ICU admission	2	0.47	(0.23, 0.92)
Safety	3	1.33	(0.84, 2.10)

Subgroup	Study (n)	RR	95% CI	
Dose	Hospitalization or ED visit			
	Mortality			
700mg B	5	0.59	(0.46, 0.76)	

	6	0.33	(0.18, 0.58)
2800mg B	1	0.32	(0.07, 1.43)
	0	NA	NA
7000mg B	1	0.33	(0.07, 1.52)
	1	1.67	(0.57, 4.86)
2800mg B+2800mgE	2	0.29	(0.15, 0.54)
	1	0.05	(0.00, 0.81)






Figure 1: Risk of publication bias. (a)hospitalization or ED visit; (b)mortality

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 1. Risk of bias summary: the review authors' judgments about each risk-of-bias item for each included cohort study.

Study	Patients' selection	Comparability between groups	Outcome or exposure factors assessment	NOS score	Risk of bias
Bariola 2021	3	2	2	7	L
Destache 2021	4	2	2	8	L
Iqbal 2021	3	2	3	8	L
Ganesh 2021	3	2	3	7	L
Kumar 2021	3	1	2	6	M
Rainwater 2021	3	1	2	6	M
Webb 2021	3	2	1	6	M

NOS: New-Castle Ottawa scale; The summary risk of bias was determined as low (NOS scores≥7), moderate (4≤NOS scores≤6), and high (NOS scores≤3).

L: low risk; M: moderate risk; H: high risk

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 2: Risk of bias summary: the review authors' judgments about each risk-of-bias item for each included randomized control trial.

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Gottlieb et al (2021)	L	L	L	U	L	L	L
Lundgren et al(2021)	L	L	L	L	L	L	L
Dougan et al (2021)	L	U	L	U	L	L	L

L: low risk; U: unclear risk; H: high risk

Table 3: GRADE summary of findings on use of intravenous immunoglobulin in COVID-19

Outcomes	Illustrative compa	rative risks* (95% CI)	Relative effect	No of Participants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	(studies)	(GRADE)	
	Control	Hospitaliazation or ED visit				
Hospitaliazation OR ED visit	Study population		RR 0.41	15201	⊕⊕⊝⊝	
Follow-up: 14-30 days	194 per 1000	79 per 1000	(0.3 to 0.56)	(9 studies)	low ^{1,2,3,4}	
	(5	58 to 108)				
	Moderate					
	200 per 1000	82 per 1000				
	(6	60 to 112)				
Death rate	Study population		RR 0.31	14347	⊕⊕⊝	
Follow-up: 14-30 days	13 per 1000	4 per 1000	0.12 to 0.77)	(8 studies)	$low^{1,2,3}$	•
		(2 to 10)				
	Moderate					
	23 per 1000	7 per				
		1000				
		(3 to 18)				
ICU adimision	Study population		RR 0.47	5073 ⊕€	⊕ ⊝⊝	
Follow-up: 30	10 per 1000	5 per 1000	0.23 to 0.92) (2	2 studies) lo	ow	
		(2 to 9)				
	Low					

	0 per 1000	0 per 1000			
		(0 to 0)			
	Moderate				
	18 per 1000	8 per 1000			
		(4 to 17)	L		
Serious advers effects	Study population			RR 1.33	RR 1.33 1814
Follow-up: 30 days	33 per 1000	44 per 1000	((0.84 to 2.1)	(0.84 to 2.1) (3 studies)
		(28 to 69)			
	Moderate				
	10 per 1000	13 per 1000			

^{*}The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

	_				
Very low quality: We are very uncertain about the estimate.					
1					
² Significant potential publication bias					
³ RR < 0.5					
⁴ Dose depend gradient					